InMed Pharmaceuticals is a pharmaceutical drug development company focused on proprietary small molecule drug candidates that are preferential signaling ligands of CB1 and CB2 endocannabinoid receptors. Its pipeline includes INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755 (cannabinol) cream for Epidermolysis Bullosa. Following the wind-down of subsidiary BayMedica's commercial operations in 2026, InMed's activities consist solely of preclinical drug development.
Q2 FY2026 — expected 2026-09-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-09-09 | 2026-06-30 | 0001213900-26-098419 | EDGAR | 73K words |
| 2025-09-23 | 2025-06-30 | 0001213900-25-090210 | EDGAR | 75K words |
| 2024-09-30 | 2024-06-30 | 0001213900-24-082843 | EDGAR | 72K words |
| 2023-09-29 | 2023-06-30 | 0001213900-23-080842 | EDGAR | 76K words |
| 2022-09-23 | 2022-06-30 | 0001213900-22-058355 | EDGAR | — |
| 2021-09-24 | 2021-06-30 | 0001213900-21-049679 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001213900-26-014996 | EDGAR | 22K words |
| 2025-11-06 | 2025-09-30 | 0001213900-25-107152 | EDGAR | 19K words |
| 2025-05-12 | 2025-03-31 | 0001213900-25-042126 | EDGAR | 26K words |
| 2025-02-12 | 2024-12-31 | 0001213900-25-013063 | EDGAR | 25K words |
| 2024-11-14 | 2024-09-30 | 0001213900-24-098445 | EDGAR | 21K words |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042467 | EDGAR | 24K words |
| 2024-02-13 | 2023-12-31 | 0001213900-24-013414 | EDGAR | 22K words |
| 2023-11-14 | 2023-09-30 | 0001213900-23-086255 | EDGAR | 19K words |
| 2023-05-15 | 2023-03-31 | 0001213900-23-039477 | EDGAR | 23K words |
| 2023-02-17 | 2022-12-31 | 0001213900-23-012859 | EDGAR | 23K words |
| 2022-11-14 | 2022-09-30 | 0001213900-22-071487 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026136 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-18 | 0001213900-26-101492 | EDGAR | 2K words |
| 2026-07-22 | 0001213900-26-080414 | EDGAR | 1K words |
| 2026-04-03 | 0001213900-26-039943 | EDGAR | 1K words |
| 2026-03-30 | 0001062993-26-001697 | EDGAR | 1K words |
| 2026-03-23 | 0001062993-26-001567 | EDGAR | 1K words |
| 2026-03-09 | 0001062993-26-001347 | EDGAR | 1K words |
| 2026-03-06 | 0001213900-26-024752 | EDGAR | 2K words |
| 2026-02-12 | 0001062993-26-000819 | EDGAR | 3K words |
| 2025-12-18 | 0001062993-25-017390 | EDGAR | 1K words |
| 2025-12-15 | 0001213900-25-121497 | EDGAR | 1K words |
220 total filings indexed. 192 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001728328 |
| Ticker | INM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
| Headquarters | Vancouver, British Columbia |
| Website | https://www.inmedpharma.com |
| Listed | 2020-11-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/INM (~200 tokens, structured JSON with cryptographic provenance)